Chinese Synthetic Biology Company Raises Nearly $14.5M
- Chaileedo Press
- Mar 22, 2023
- 2 min read
Lumy Bio is focusing on the production of active and sustainable ingredients. In the future, it intends to launch a variety of products to promote the inorganization of ingredients and reduce carbon footprint.
Light-driven synthetic biology company Shanghai Lumy Bio Technology Co. Ltd. (hereinafter referred to as "Lumy Bio") announced the completion of a Pre-A round of financing of nearly 100 million yuan ($14.5 million), with Vitalbridgh as the exclusive investor and Fanzhuo Capital as the financial advisor for this round of financing.
The new round of financing is mainly used for the deploying pipeline, constructing the carbon-negative process base and expanding the talent team.
According to public information, Lumy Bio, founded in 2021, focuses on the development of innovative synthetic organisms for light-driven CO2 recovery. Through rational design and multi-dimensional editing of the photosynthetic microorganism cyanobacteria, Lumy Bio has developed nearly 100 "negative carbon" cell factories that use light energy directly to efficiently convert CO2 into target products. This new generation of synthetic biotechnology attempts to "make compounds from air and reshape the world with recycled carbon".
Furthermore, the core R&D team of Lumy Bio has accumulated more than ten years of experience in photosynthetic biomodification, artificial photosynthetic colony development and metabolic modeling. It possesses a number of core technologies in the field of light-driven synthetic biology. It has built a library of photosynthetic cell factories to enable the targeted manufacture of pharmaceutical ingredients, chemical ingredients and degradable materials using CO2.
At this stage, Lumy Bio focuses on functional active ingredients, healthcare nutrition and sustainable agriculture. It has already realized the ecological closed loop of the light-driven synthetic biology platform from R&D to application and established several business pipelines such as ergothioneine, sakuranetin and bisdemethoxy curcumin. It is reported that Lumy Bio has signed commercial cooperation agreements with a number of industry heads and hopes to launch a variety of products in the coming years in collaboration with relevant industry leaders to promote inorganic feedstock and reduce carbon footprint.
It is worth mentioning that synthetic biology uses third-generation feedstock (e.g. carbon dioxide, methanol) for "carbon-negative production" of tri-generation biorefineries to obtain fine chemicals in a greener way and reduce carbon emissions. This technology is favoured by many leading international brands such as Unilever, L'Oreal and Lululemon.
Comments